益盛药业 (002566.SZ) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	659.7M	640.2M	668.5M	853.7M	830.0M
Cost of Revenue	171.2M	166.5M	170.6M	224.2M	216.5M
Gross Profit	488.4M	473.7M	497.8M	629.5M	613.5M
Operating Expenses
R&D Expense	15.8M	15.1M	16.2M	18.7M	18.8M
SG&A Expense	—	—	—	—	—
General & Admin Expense	105.2M	99.7M	98.1M	100.1M	100.4M
Selling & Marketing Expense	330.1M	317.4M	332.0M	411.4M	388.9M
Other Expenses	—	—	—	—	—
Total Operating Expenses	479.8M	460.7M	469.9M	546.8M	530.5M
Cost and Expenses	651.0M	627.2M	640.5M	771.0M	747.1M
Operating Income (EBIT)	35.9M	31.3M	61.4M	115.7M	102.7M
Non-Operating
Interest Income	—	—	—	—	—
Interest Expense	—	—	—	—	—
Net Interest Income	—	—	—	—	—
Other Non-Op Income/Expense	—	—	—	—	—
Non-Operating Income (excl Interest)	—	—	—	—	—
EBT (Pre-Tax Income)	34.7M	30.1M	59.5M	111.8M	101.2M
Income Tax Expense	1.5M	1.1M	8.9M	15.7M	12.9M
Bottom Line
Net Income	33.3M	29.0M	52.1M	94.7M	83.1M
Earnings from Cont. Ops	33.1M	28.9M	50.7M	96.1M	88.3M
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	33.3M	29.0M	52.1M	94.7M	83.1M
Per Share
Basic EPS	CN¥0.10	CN¥0.09	CN¥0.16	CN¥0.29	CN¥0.25
Diluted EPS	CN¥0.10	CN¥0.09	CN¥0.16	CN¥0.29	CN¥0.25
Revenue Per Share	CN¥1.99	CN¥1.93	CN¥2.02	CN¥2.58	CN¥2.51
Shares
Basic Shares Outstanding	330.8M	331.0M	330.9M	331.0M	330.9M
Diluted Shares Outstanding	330.8M	331.0M	330.9M	331.0M	330.9M
Profitability Metrics
EBITDA	—	70.5M	104.7M	162.5M	143.7M
D&A	—	39.2M	43.4M	46.7M	41.0M
EBIT	—	—	—	—	—

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026